Navigation Links
Boston Heart Lab Named 'Most Promising Early Stage Company' 2009 by Silicom Ventures
Date:6/29/2009

FRAMINGHAM, Mass., June 29 /PRNewswire/ -- Boston Heart Lab, a pioneer in specialized diagnostics for patients with heart disease, was named "Most Promising Early Stage Company" by Silicom Ventures at the angel investment organization's 2009 Investment Summit, which took place June 2-3, 2009, at Stanford University in California. A four-judge panel selected Boston Heart Lab after evaluating the 20 participating companies for quality of management, vision, execution abilities, and the potential scope of the opportunities. Boston Heart Lab Chief Executive Officer, Wolfgang Daum, Ph.D., accepted the award on behalf of the start-up company, which has seen strong revenues since it began clinical operations in August 2008.

"We're very honored to receive this prestigious award, which is a testament both to the important work our Boston Heart Lab team has done to develop and launch our advanced cardiovascular diagnostic and lipid-testing program, and to the relevance of the services we provide to the marketplace," said Dr. Daum. "While there are other providers of esoteric testing for cardiology, we employ the most-advanced technology available with our proprietary two-dimensional gel electrophoresis of HDL particles and plasma sterol analysis. We deliver clinicians a more complete picture of the patient's health status -- our test results and analyses are the critical building blocks for a personalized treatment plan designed to offer patients the best opportunity for improved health outcomes. This includes more than 35 proprietary tests to assess the patient's cardiac health and risk profile, and a treatment algorithm (Boston Heart Navigator) based on the latest peer-reviewed scientific data."

Commenting on the award, Silicom Ventures' Founder and Managing Director, Gadi Behar, said, "The 2009 Investment Summit showcased 20 impressive early-stage companies in various fields -- from alternative energy and social networking to life sciences. The four-judge panel was unanimous in choosing Boston Heart Lab for its top award in recognition of the start-up's early success in turning the promise of personalized medicine into a reality for cardiac patients. There are 19 million people in the U.S. alone with established heart disease (patients who have had heart attack or stroke) that could benefit from Boston Heart Lab's services, not to mention the 45 million at-risk for cardiac disease. Boston Heart Lab's work will become increasingly important as our healthcare system focuses more and more on outcomes-based medicine to save health dollars and improve outcomes for patients." The judges for the award were three angel investors with extensive investment experience and a venture capitalist partner from Claremont Creek Ventures.

About Silicom Ventures (www.silicomventures.com)

Silicom Ventures is one of the leading angel investment organizations in the United States. It links experienced investors (high-tech executives) and venture capitalists with entrepreneurs from around the globe and helps individual angels pool their efforts to gain access to better ventures and better investment deals. Silicom Ventures is leveraging its large network of investors, venture capitalists, industry executives, and technology experts offering entrepreneurs a highly effective screening and early funding process. Beyond funding, Silicom Ventures connects qualified companies with potential business partners, employers, and employees, and technical, professional, and business advisors.

About Boston Heart Lab (www.bostonheartlab.com)

Boston Heart Lab enables cardiologists and other clinicians to prescribe personalized treatment plans for cardiovascular disease and lipid disorders that offer patients the best opportunity for improved health outcomes, based on a panel of tests that provides the most comprehensive assessment available detailing the cause and state of the patient's disease. The company's proprietary two-dimensional gel electrophoresis of HDL particles reveals the entire reverse cholesterol metabolism (HDL) to sub classify the disease; while its proprietary plant sterol analysis evaluates how well the patient produces and absorbs cholesterol. Boston Heart Lab currently offers more than 35 proprietary, state-of-the-art tests to assess the patient's cardiac health and risk profile, and a treatment algorithm for developing a tailored treatment protocol (Boston Heart Navigator) based on the latest peer-reviewed scientific data. A privately held company, Boston Heart Lab began clinical operations after receiving its CLIA license in July 2008.

Media Contact: Caroline Grossman - 781.771.5579 - caroline.grossman@gmail.com

Company Contact: Wolfgang Daum - 978-273-8266 - wdaum@bostonheartlab.com


'/>"/>
SOURCE Boston Heart Lab
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Boston Cardinal OMalley Withdraws Caritas Christi From Potential Abortion Scandal
2. Boston Scientific Announces Retirement of Jim Tobin and Appointment of Ray Elliott as New President and CEO
3. Childrens Hospital Boston, CompuCyte Corporation Establish International Quantitative Imaging Cytometry Center
4. American Life League: Revelations in Boston Archdiocese Caritas Scandal
5. Greater Boston unites to transform health care
6. Boston Scientifics Urology/Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting
7. Fifth Annual Games for Health Conference Kicks Off in Boston
8. Clock Ticking In Boston Archdiocese Abortion Scandal
9. Boston Medical Center Selects Bank of America to Assist with Payments Transformation
10. NYP/Weill Cornell physician-scientists present at 2009 American Transplant Congress in Boston
11. Boston Scientific Announces Two Directors Leave Board as Burns Named CEO of Xerox and Johnson Confirmed as Under Secretary of Energy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... 2017 , ... The world-class designers of Happy Gadget Alert ... lifesaving device for the everyday use of parents worldwide. It is a lightweight, ... a child’s vital signs, and detect unusual symptoms or physical patterns. This innovative ...
(Date:4/24/2017)... ... April 24, 2017 , ... Salus Telehealth, Inc. ... company’s VideoMedicine mobile platform has launched Quick Care, a new service offering on-demand ... Care provides patients with the option to request and begin a consultation with ...
(Date:4/24/2017)... ... April 24, 2017 , ... According to the ... now claim the lives of 62 Americans each day.(1) Yet since 2011, the ... distributors, pharmacies and prescribers by more than half.(2) Novus Medical Detox Center ...
(Date:4/24/2017)... ... 24, 2017 , ... MAP Health Management announced today a ... with addiction who are served by MAP’s patient engagement ecosystem. Lief Therapeutics is ... heart and breath rates to identify anxiety levels and can provide biofeedback exercises ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... health of individuals with HIV because it is not known to have significant ... have favorable effects to both lower cholesterol levels and dampen inflammation in the ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... and BLOOMINGTON, Minn. ... (NASDAQ: IMMY ) ("Imprimis"), an ophthalmology-focused ... Lens ("Precision Lens"), today announced the signing of ... agreement, Precision Lens will deploy a dedicated sales ... geographies in the U.S., primarily focused in 13 ...
(Date:4/18/2017)... 18, 2017 Research and Markets has ... States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast to 2023" ... ... equipment revenues as well as growth in the number of ... value to market participants that design and manufacture molecular imaging ...
(Date:4/18/2017)... SALT LAKE CITY , April 18, 2017 /PRNewswire/ ... that combines innovative biological science with machine learning techniques ... it has hired Dr. Yolanda Chong as ... six years at Johnson & Johnson in ... led a team that focused on applying high-dimensional biological ...
Breaking Medicine Technology: